Additional Relevant Details IONS earned a  2.15M milestone payment from Biogen (BIIB) for completing enrollment for Phase 3 Nusinersen trials, scheduled to finish by July 2017.  Nusinersen is a Fast Track and Orphan Drug tagged drug designed to combat the effects of Spinal Muscular Atrophy (SMA) by producing a functional SMN protein.

clinicaltrials.gov record in source